Vertaling van "for the treatment of postmenopausal " (Frans → Nederlands) :

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporis.

Gauthier K, Bai A, Perras C et al ; Canadian Agency for Drugs and Technologies in Health. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms.
postmenopausal osteoporosis : clinical effectiveness and harms.

Postmenopausal ♀ Mean age 73 y T-score < -2.5 or radiologic evidence of vertebral #
- T-score < -2.5 or radiologic evidence of vertebral #

Postmenopausal ♀ T-score ≤ -2 or previous vertebral #
- T-score ≤ -2 or previous vertebral #

Guidelines for the diagnosis and manegement of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

Bon à savoir: traitement de substitution hormonale et risque de cancer du sein invasif. Folia Pharmacotherapeutica 2011; 38:4-5. [http ...]
Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Menopur® (gonadotrophine humaine de la postménopause), gonadotrophine d’origine urinaire.
Menopur® (menselijk menopauzaal gonadotropine), gonadotropine van urinaire oorsprong,

Arch Intern Med 2006; 166:357-65. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.

En fonction de la situation clinique, de la charge virale et du taux plasmatique de lymphocytes CD4, le traitement comprend généralement deux inhibiteurs nucléosidiques de la transcriptase inverse, associés à un inhibiteur de la protéase virale ou à un inhibiteur non nucléosidique de la transcriptase inverse (trithérapie ou " HAART”, c.-à-d. Highly Active AntiRetroviral Treatment).
In functie van de klinische toestand, de virale belasting (viral load) en het aantal CD4-lymfocyten in het plasma worden meestal twee nucleoside reverse-transcriptaseremmers gecombineerd met een protease-inhibitor of een niet-nucleoside reverse-transcriptaseremmer (triple therapy of " HAART”, d.w.z. Highly Active AntiRetroviral Treatment).

D’après O. Rascol et al.: Treatment interventions for Parkinson’s disease: an evidence based assessment.
Naar O. Rascol et al.: Treatment interventions for Parkinson’s disease: an evidence based assessment.